个人中心 - 老虎社区

Williamting

Trying to make some Kopi money

IP属地：未知

帖子 · 2帖子 · 2
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- WilliamtingWilliamting
  ·2021-08-22
  Novavax should have potential for great growth USA pension funds have taken up some stakes in thiscounter.👍👍
  4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4只超高速增长股票预计到2025年销售额将增长1,100%（或更多）</blockquote>
  Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade. Key P
  4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4只超高速增长股票预计到2025年销售额将增长1,100%（或更多）</blockquote>
  1,916 评论
  6
  分享
  举报
- WilliamtingWilliamting
  ·2021-08-22
  Speculative counters. In the WSB’s list!
  非常抱歉，此主贴已删除
  2,151 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3573440441801146","uuid":"3573440441801146","gmtCreate":1610363213542,"gmtModify":1617331188877,"name":"Williamting","pinyin":"williamting","introduction":"","introductionEn":"","signature":"Trying to make some Kopi money","avatar":"https://static.tigerbbs.com/93f4f81864155daee4e7c8aac19c8f21","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.23","exceedPercentage":"93.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":832291331,"gmtCreate":1629633942923,"gmtModify":1631884988920,"author":{"id":"3573440441801146","authorId":"3573440441801146","name":"Williamting","avatar":"https://static.tigerbbs.com/93f4f81864155daee4e7c8aac19c8f21","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573440441801146","authorIdStr":"3573440441801146"},"themes":[],"htmlText":"Novavax should have potential for great growth USA pension funds have taken up some stakes in thiscounter.👍👍","listText":"Novavax should have potential for great growth USA pension funds have taken up some stakes in thiscounter.👍👍","text":"Novavax should have potential for great growth USA pension funds have taken up some stakes in thiscounter.👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/832291331","repostId":"1122814365","repostType":2,"repost":{"id":"1122814365","kind":"news","pubTimestamp":1629292156,"share":"https://www.laohu8.com/m/news/1122814365?lang=zh_CN&edition=full","pubTime":"2021-08-18 21:09","market":"us","language":"en","title":"4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4只超高速增长股票预计到2025年销售额将增长1,100%（或更多）</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122814365","media":"Motley Fool","summary":"Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.\n\nKey P","content":"<p>  <b>Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.</b>  <b>Key Points</b></p><p><blockquote><b>到十年中期，这些快节奏股票的收入应该会飙升1,100%至4,200%。</b><b>要点</b></blockquote></p><p> <ul>  <li>Rapid sales growth doesn't always tell you the full story about a company.</li> </ul> For the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.</p><p><blockquote><ul><li>快速的销售增长并不总是能告诉你一家公司的全部情况。</li></ul>过去12年来，成长型股票在华尔街风靡一时，这是有充分理由的。历史上较低的贷款利率和充足的廉价资本渠道推动了快节奏公司的招聘、创新甚至收购。</blockquote></p><p> But for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.</p><p><blockquote>但对于一些成长型股票来说，收入的预期增长才刚刚开始。根据华尔街的一致估计，以下四只高速增长股票的销售额预计将在未来三到五年内增长1,100%至4,200%以上。</blockquote></p><p> <b>Novavax: Implied sales growth of 1,337% by 2025</b></p><p><blockquote><b>Novavax：到2025年隐含销售额增长1,337%</b></blockquote></p><p> Biotech stocksare always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developer<b>Novavax</b>(NASDAQ:NVAX)is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.</p><p><blockquote>随着第一个药物获得批准，生物科技股的销售额从零飙升至英雄始终是一个不错的选择。临床阶段药物开发商<b>Novavax</b>（纳斯达克：NVAX）预计其冠状病毒疾病2019（COVID-19）疫苗NVX-CoV2373将获得紧急使用授权（EUA）批准，预计将做得更多。据华尔街报道，Novavax的销售额可能会从2020年的近4.76亿美元跃升至2025年的约68.4亿美元。</blockquote></p><p> To date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Theeffectiveness of Novavax's vaccinemakes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy --<b>Johnson &amp; Johnson</b>&nbsp;and<b>AstraZeneca</b>&nbsp;-- to the back of the line.</p><p><blockquote>迄今为止，Novavax已经为其COVID-19疫苗进行了两项大规模临床试验。3月份，英国的3期试验数据显示疫苗效力(VE)为89.7%。在美国和墨西哥进行的第二项3期研究的数据于6月发布，显示VE非常相似，为90.4%。Novavax疫苗的有效性使得它很可能很快在美国、英国和欧洲等发达市场获得授权，并可能在新兴市场发挥关键作用。Novavax也可能会推出感知效力较低的疫苗——<b>强生公司</b>和<b>阿斯利康</b>--到队伍的后面。</blockquote></p><p> The only real drag for Novavax shareholders has been the company'snumerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.</p><p><blockquote>Novavax股东唯一真正的拖累是该公司多次推迟申请EUA。该公司最初预计将于第二季度在美国寻求EUA，现在预计将在第四季度提交适当的文件。人们还担心该公司将疫苗生产提高到满负荷的时间表。</blockquote></p><p> Nevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.</p><p><blockquote>尽管如此，一两个季度的延迟不会阻碍Novavax的长期前景，这似乎受到疾病变种发展的提振。该公司快速开发疫苗的能力，以及将流感和COVID-19结合到单一加强注射中的早期研究，应该会让Novavax在未来很长一段时间内保持领先地位。</blockquote></p><p> <b>Blink Charging: Implied sales growth of 2,352% by 2025</b></p><p><blockquote><b>Blink Charging：到2025年隐含销售额增长2,352%</b></blockquote></p><p> Another growth stocks with (pun intended) supercharged sales growth potential over the next five years is<b>Blink Charging</b>(NASDAQ:BLNK). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.</p><p><blockquote>另一只在未来五年内具有强劲销售增长潜力的成长型股票是<b>闪烁充电</b>（纳斯达克：BLNK）。Blink提供电动汽车(EV)充电基础设施，并拥有充电站网络。</blockquote></p><p> The logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs.&nbsp; As the electrification of America takes shape, demand for charging infrastructureis only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.</p><p><blockquote>Blink增长背后的逻辑很容易理解。去年，在美国注册的所有新车中有1.8%是电动汽车。但IHS Markit的一项研究预测，到2025年，所有新车注册量的10%将是电动汽车。随着美国电气化的形成，对充电基础设施的需求只会越来越高。未来几十年，Blink Charging等辅助电动汽车厂商应该有足够的空间来利用这一趋势。</blockquote></p><p> Based on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.</p><p><blockquote>根据华尔街的普遍估计，Blink Charging的销售额预计将从2020年报告的620万美元增长到十年中期的1.52亿美元。对于那些在家记分的人来说，收入增长了2,352%。</blockquote></p><p> However, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company alsodoesn't appear to be investing any of its cash into research and development.&nbsp; With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.</p><p><blockquote>然而，Blink的未来还远未确定。其目前的市值是2025年预计销售额的9倍，而且还没有特别接近盈利。该公司似乎也没有将任何现金投入研发。由于没有真正的脱颖而出手段，Blink Charging很可能会被竞争对手远远甩在身后。</blockquote></p><p> <b>Jushi Holdings: Implied sales growth of 1,101% by 2024</b></p><p><blockquote><b>巨石控股：到2024年隐含销售额增长1101%</b></blockquote></p><p> U.S.marijuana stocks&nbsp;are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operator<b>Jushi Holdings</b>(OTC:JUSHF). According to estimates from&nbsp;<b>FactSet</b>, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.</p><p><blockquote>随着新州大麻合法化以及已经合法化的州从有机增长中受益，美国大麻股票是未来三到五年实现三位数总销售额增长的绝佳选择。但您可以忘记多州运营商三位数的销售增长<b>巨石控股</b>（场外交易代码：JUSHF）。据估计<b>FactSet</b>巨石预计到2024年年收入将达到9.69亿美元，比去年的8070万美元销售额增长1,101%。</blockquote></p><p></p><p> Operating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.</p><p><blockquote>在利润丰厚的美国市场运营势必会给巨石带来提振。我们已经看到36个州以某种方式将大麻合法化，其中18个州已经通过立法，允许消费和/或零售成人用大麻。如果New Frontier Data关于美国大麻行业的最新报告被证明是准确的，那么到2025年，合法大麻销售额可能会年均增长21%，最终达到410亿美元以上。</blockquote></p><p> Jushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's&nbsp;core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.</p><p><blockquote>目前，巨石在大麻领域是一个相对较小的参与者。它有20家正在运营的药房，但今年年底可能会接近30家，包括有机开业和收购。该公司的核心重点是三个有限许可州：弗吉尼亚州、宾夕法尼亚州和伊利诺伊州。前者根据管辖权发放许可证，而后两者限制分配的零售和种植许可证的总数。通过瞄准有限许可州，巨石将在一定程度上免受财力雄厚的竞争对手的影响。</blockquote></p><p> Similar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the&nbsp;biggest bargains in the cannabis industry.</p><p><blockquote>与Novavax类似，巨石预计将在2022年实现经常性盈利。这看起来是大麻行业最大的便宜货之一。</blockquote></p><p> <b>Riot Blockchain: Implied sales growth of 4,231% by 2023</b></p><p><blockquote><b>Riot区块链：到2023年隐含销售额增长4,231%</b></blockquote></p><p> The last hypergrowth stock expected to deliver insane revenue growth in the coming years is&nbsp;cryptocurrency miningcompany<b>Riot Blockchain</b>(NASDAQ:RIOT). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.</p><p><blockquote>预计未来几年收入疯狂增长的最后一只高速增长股票是加密货币矿业公司<b>防暴区块链</b>（纳斯达克：暴动）。在报告2020年全年销售额仅为1210万美元后，华尔街预计Riot到2023年将带来5.24亿美元的收入。短短三年内销售额增长了4,200%以上。</blockquote></p><p> Cryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring becauseit's building up its farmto mine&nbsp;<b>Bitcoin</b>(CRYPTO:BTC), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.</p><p><blockquote>加密货币矿工是使用高性能计算机求解复杂数学方程以验证称为区块的交易组的个人或公司。为此，加密矿工将获得整体奖励。就Riot而言，它的收入正在飙升，因为它正在建设农场到矿山<b>比特币</b>（加密货币：BTC），按市值计算，全球最大的数字货币。截至8月15日，比特币区块奖励相当于6.25比特币，价值约287,000美元。</blockquote></p><p> As of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022.</p><p><blockquote>截至7月底，Riot Blockchain在其资产负债表上持有约2,687个比特币（这些是该公司自成立以来一直在开采的代币），计划到9月初有25,946个蚂蚁矿机投入运营。Riot Blockchain的目标是到2022年第四季度让其全部矿工（81,146台蚂蚁矿工）投入运营。</blockquote></p><p> While the sales growth in Bitcoin mining stocks is undeniable, therisks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.</p><p><blockquote>虽然比特币矿业股的销售增长是不可否认的，但其风险也不容忽视。Riot不依赖创新，而是完全依赖比特币投资者的情绪和代币的价格。在过去十年中，我们还目睹了比特币三次至少80%的下降，这可能会压垮Riot Blockchain的运营模式。</blockquote></p><p> But the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.</p><p><blockquote>但真正令人担忧的是，进入加密货币挖矿领域没有障碍，到2024年，比特币区块奖励将减半至3.125个代币。这是一个竞争激烈、回报不断减少的领域。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4只超高速增长股票预计到2025年销售额将增长1,100%（或更多）</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4只超高速增长股票预计到2025年销售额将增长1,100%（或更多）</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-08-18 21:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.</b>  <b>Key Points</b></p><p><blockquote><b>到十年中期，这些快节奏股票的收入应该会飙升1,100%至4,200%。</b><b>要点</b></blockquote></p><p> <ul>  <li>Rapid sales growth doesn't always tell you the full story about a company.</li> </ul> For the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.</p><p><blockquote><ul><li>快速的销售增长并不总是能告诉你一家公司的全部情况。</li></ul>过去12年来，成长型股票在华尔街风靡一时，这是有充分理由的。历史上较低的贷款利率和充足的廉价资本渠道推动了快节奏公司的招聘、创新甚至收购。</blockquote></p><p> But for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.</p><p><blockquote>但对于一些成长型股票来说，收入的预期增长才刚刚开始。根据华尔街的一致估计，以下四只高速增长股票的销售额预计将在未来三到五年内增长1,100%至4,200%以上。</blockquote></p><p> <b>Novavax: Implied sales growth of 1,337% by 2025</b></p><p><blockquote><b>Novavax：到2025年隐含销售额增长1,337%</b></blockquote></p><p> Biotech stocksare always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developer<b>Novavax</b>(NASDAQ:NVAX)is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.</p><p><blockquote>随着第一个药物获得批准，生物科技股的销售额从零飙升至英雄始终是一个不错的选择。临床阶段药物开发商<b>Novavax</b>（纳斯达克：NVAX）预计其冠状病毒疾病2019（COVID-19）疫苗NVX-CoV2373将获得紧急使用授权（EUA）批准，预计将做得更多。据华尔街报道，Novavax的销售额可能会从2020年的近4.76亿美元跃升至2025年的约68.4亿美元。</blockquote></p><p> To date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Theeffectiveness of Novavax's vaccinemakes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy --<b>Johnson &amp; Johnson</b>&nbsp;and<b>AstraZeneca</b>&nbsp;-- to the back of the line.</p><p><blockquote>迄今为止，Novavax已经为其COVID-19疫苗进行了两项大规模临床试验。3月份，英国的3期试验数据显示疫苗效力(VE)为89.7%。在美国和墨西哥进行的第二项3期研究的数据于6月发布，显示VE非常相似，为90.4%。Novavax疫苗的有效性使得它很可能很快在美国、英国和欧洲等发达市场获得授权，并可能在新兴市场发挥关键作用。Novavax也可能会推出感知效力较低的疫苗——<b>强生公司</b>和<b>阿斯利康</b>--到队伍的后面。</blockquote></p><p> The only real drag for Novavax shareholders has been the company'snumerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.</p><p><blockquote>Novavax股东唯一真正的拖累是该公司多次推迟申请EUA。该公司最初预计将于第二季度在美国寻求EUA，现在预计将在第四季度提交适当的文件。人们还担心该公司将疫苗生产提高到满负荷的时间表。</blockquote></p><p> Nevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.</p><p><blockquote>尽管如此，一两个季度的延迟不会阻碍Novavax的长期前景，这似乎受到疾病变种发展的提振。该公司快速开发疫苗的能力，以及将流感和COVID-19结合到单一加强注射中的早期研究，应该会让Novavax在未来很长一段时间内保持领先地位。</blockquote></p><p> <b>Blink Charging: Implied sales growth of 2,352% by 2025</b></p><p><blockquote><b>Blink Charging：到2025年隐含销售额增长2,352%</b></blockquote></p><p> Another growth stocks with (pun intended) supercharged sales growth potential over the next five years is<b>Blink Charging</b>(NASDAQ:BLNK). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.</p><p><blockquote>另一只在未来五年内具有强劲销售增长潜力的成长型股票是<b>闪烁充电</b>（纳斯达克：BLNK）。Blink提供电动汽车(EV)充电基础设施，并拥有充电站网络。</blockquote></p><p> The logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs.&nbsp; As the electrification of America takes shape, demand for charging infrastructureis only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.</p><p><blockquote>Blink增长背后的逻辑很容易理解。去年，在美国注册的所有新车中有1.8%是电动汽车。但IHS Markit的一项研究预测，到2025年，所有新车注册量的10%将是电动汽车。随着美国电气化的形成，对充电基础设施的需求只会越来越高。未来几十年，Blink Charging等辅助电动汽车厂商应该有足够的空间来利用这一趋势。</blockquote></p><p> Based on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.</p><p><blockquote>根据华尔街的普遍估计，Blink Charging的销售额预计将从2020年报告的620万美元增长到十年中期的1.52亿美元。对于那些在家记分的人来说，收入增长了2,352%。</blockquote></p><p> However, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company alsodoesn't appear to be investing any of its cash into research and development.&nbsp; With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.</p><p><blockquote>然而，Blink的未来还远未确定。其目前的市值是2025年预计销售额的9倍，而且还没有特别接近盈利。该公司似乎也没有将任何现金投入研发。由于没有真正的脱颖而出手段，Blink Charging很可能会被竞争对手远远甩在身后。</blockquote></p><p> <b>Jushi Holdings: Implied sales growth of 1,101% by 2024</b></p><p><blockquote><b>巨石控股：到2024年隐含销售额增长1101%</b></blockquote></p><p> U.S.marijuana stocks&nbsp;are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operator<b>Jushi Holdings</b>(OTC:JUSHF). According to estimates from&nbsp;<b>FactSet</b>, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.</p><p><blockquote>随着新州大麻合法化以及已经合法化的州从有机增长中受益，美国大麻股票是未来三到五年实现三位数总销售额增长的绝佳选择。但您可以忘记多州运营商三位数的销售增长<b>巨石控股</b>（场外交易代码：JUSHF）。据估计<b>FactSet</b>巨石预计到2024年年收入将达到9.69亿美元，比去年的8070万美元销售额增长1,101%。</blockquote></p><p></p><p> Operating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.</p><p><blockquote>在利润丰厚的美国市场运营势必会给巨石带来提振。我们已经看到36个州以某种方式将大麻合法化，其中18个州已经通过立法，允许消费和/或零售成人用大麻。如果New Frontier Data关于美国大麻行业的最新报告被证明是准确的，那么到2025年，合法大麻销售额可能会年均增长21%，最终达到410亿美元以上。</blockquote></p><p> Jushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's&nbsp;core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.</p><p><blockquote>目前，巨石在大麻领域是一个相对较小的参与者。它有20家正在运营的药房，但今年年底可能会接近30家，包括有机开业和收购。该公司的核心重点是三个有限许可州：弗吉尼亚州、宾夕法尼亚州和伊利诺伊州。前者根据管辖权发放许可证，而后两者限制分配的零售和种植许可证的总数。通过瞄准有限许可州，巨石将在一定程度上免受财力雄厚的竞争对手的影响。</blockquote></p><p> Similar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the&nbsp;biggest bargains in the cannabis industry.</p><p><blockquote>与Novavax类似，巨石预计将在2022年实现经常性盈利。这看起来是大麻行业最大的便宜货之一。</blockquote></p><p> <b>Riot Blockchain: Implied sales growth of 4,231% by 2023</b></p><p><blockquote><b>Riot区块链：到2023年隐含销售额增长4,231%</b></blockquote></p><p> The last hypergrowth stock expected to deliver insane revenue growth in the coming years is&nbsp;cryptocurrency miningcompany<b>Riot Blockchain</b>(NASDAQ:RIOT). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.</p><p><blockquote>预计未来几年收入疯狂增长的最后一只高速增长股票是加密货币矿业公司<b>防暴区块链</b>（纳斯达克：暴动）。在报告2020年全年销售额仅为1210万美元后，华尔街预计Riot到2023年将带来5.24亿美元的收入。短短三年内销售额增长了4,200%以上。</blockquote></p><p> Cryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring becauseit's building up its farmto mine&nbsp;<b>Bitcoin</b>(CRYPTO:BTC), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.</p><p><blockquote>加密货币矿工是使用高性能计算机求解复杂数学方程以验证称为区块的交易组的个人或公司。为此，加密矿工将获得整体奖励。就Riot而言，它的收入正在飙升，因为它正在建设农场到矿山<b>比特币</b>（加密货币：BTC），按市值计算，全球最大的数字货币。截至8月15日，比特币区块奖励相当于6.25比特币，价值约287,000美元。</blockquote></p><p> As of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022.</p><p><blockquote>截至7月底，Riot Blockchain在其资产负债表上持有约2,687个比特币（这些是该公司自成立以来一直在开采的代币），计划到9月初有25,946个蚂蚁矿机投入运营。Riot Blockchain的目标是到2022年第四季度让其全部矿工（81,146台蚂蚁矿工）投入运营。</blockquote></p><p> While the sales growth in Bitcoin mining stocks is undeniable, therisks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.</p><p><blockquote>虽然比特币矿业股的销售增长是不可否认的，但其风险也不容忽视。Riot不依赖创新，而是完全依赖比特币投资者的情绪和代币的价格。在过去十年中，我们还目睹了比特币三次至少80%的下降，这可能会压垮Riot Blockchain的运营模式。</blockquote></p><p> But the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.</p><p><blockquote>但真正令人担忧的是，进入加密货币挖矿领域没有障碍，到2024年，比特币区块奖励将减半至3.125个代币。这是一个竞争激烈、回报不断减少的领域。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/18/4-hypergrowth-stocks-increase-sales-1100-by-2025/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIOT":"Riot Platforms","BLNK":"Blink Charging","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/18/4-hypergrowth-stocks-increase-sales-1100-by-2025/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122814365","content_text":"Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.\n\nKey Points\n\nRapid sales growth doesn't always tell you the full story about a company.\n\nFor the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.\nBut for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.\nNovavax: Implied sales growth of 1,337% by 2025\nBiotech stocksare always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developerNovavax(NASDAQ:NVAX)is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.\nTo date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Theeffectiveness of Novavax's vaccinemakes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy --Johnson & Johnson andAstraZeneca -- to the back of the line.\nThe only real drag for Novavax shareholders has been the company'snumerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.\nNevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.\nBlink Charging: Implied sales growth of 2,352% by 2025\nAnother growth stocks with (pun intended) supercharged sales growth potential over the next five years isBlink Charging(NASDAQ:BLNK). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.\nThe logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs.  As the electrification of America takes shape, demand for charging infrastructureis only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.\nBased on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.\nHowever, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company alsodoesn't appear to be investing any of its cash into research and development.  With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.\nJushi Holdings: Implied sales growth of 1,101% by 2024\nU.S.marijuana stocks are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operatorJushi Holdings(OTC:JUSHF). According to estimates from FactSet, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.\nOperating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.\nJushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.\nSimilar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the biggest bargains in the cannabis industry.\nRiot Blockchain: Implied sales growth of 4,231% by 2023\nThe last hypergrowth stock expected to deliver insane revenue growth in the coming years is cryptocurrency miningcompanyRiot Blockchain(NASDAQ:RIOT). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.\nCryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring becauseit's building up its farmto mine Bitcoin(CRYPTO:BTC), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.\nAs of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022.\nWhile the sales growth in Bitcoin mining stocks is undeniable, therisks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.\nBut the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.","news_type":1,"symbols_score_info":{"BLNK":0.9,"BLNKW":0.9,"NVAX":0.9,"RIOT":0.9}},"isVote":1,"tweetType":1,"viewCount":1916,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832293937,"gmtCreate":1629633798029,"gmtModify":1633683657211,"author":{"id":"3573440441801146","authorId":"3573440441801146","name":"Williamting","avatar":"https://static.tigerbbs.com/93f4f81864155daee4e7c8aac19c8f21","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573440441801146","authorIdStr":"3573440441801146"},"themes":[],"htmlText":"Speculative counters. &nbsp;In&nbsp;the WSB’s list!","listText":"Speculative counters. &nbsp;In&nbsp;the WSB’s list!","text":"Speculative counters. In the WSB’s list!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/832293937","repostId":"1171001359","repostType":2,"isVote":1,"tweetType":1,"viewCount":2151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}